A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere
- 308 Downloads
Docetaxel and capecitabine combination is synergistic in preclinical models. We investigated the efficacy and toxicity of this combination as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma (mPC), pretreated with gemcitabine-based chemotherapy.
Eligible patients were treated with capecitabine 800 mg/m2 orally PO bid on days 1–14 in combination with intravenous docetaxel 30 mg/m2 on days 1 and 8 of each 21-day cycle. The primary end point was overall response rate. Using a three-stage sequential design, two interim analyses for early stopping due to lack of efficacy were planned and conducted after 13 and 26 patients were accrued. Secondary end points included time to treatment failure, progression-free survival (PFS), overall survival (OS) and 50 % drop in CA19-9 levels.
Forty-three patients were evaluable for toxicity and 42 evaluable for response, at a median age of 64 years. The majority of patients (74 %) had ECOG PS 0-1. Six patients (14 %) achieved a partial tumor response, and stable disease for ≥2 cycles was observed in 59 % of patients (n = 25). Thirty-five percent (n = 11/31) of patients had a ≥50 % decrease in CA19-9 levels. The median PFS was 3.7 months (95 % CI 2.1–4.3 months), and the median OS was 5.3 months (95 % CI 4.3–8.6 months). Treatment was generally well tolerated. Grade 3 toxicity and grade 4 toxicity were seen in 45 and 5 % of patients, respectively. One patient had a potential treatment-related mortality.
The combination of capecitabine and docetaxel is active and well tolerated in mPC patients pretreated with gemcitabine-based therapy.
KeywordsPancreatic cancer Gemcitabine pretreated Second-line chemotherapy Capecitabine Docetaxel
- 3.Von Hoff DD, Ervin T, Arena FP, Gabriela Chiorean E, Infante JR, Moore MJ et al (2013) Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates. In: ASCO annual meeting. Chicago, IL. J Clin Oncol 31: abstract 4005Google Scholar
- 4.Oettle H, Pelzer U, Stieler J et al (2005) Oxaliplatin/folinic acid/5-fluorouracil [24 h] (OFF) plus best supportive care versus best supportive care alone (BSC) in second-line therapy of gemcitabine-pretreated advanced pancreatic cancer (CONKO 003). In: ASCO annual meeting proceedings 2005. J Clin Oncol 23: abstract 4031Google Scholar
- 5.Pelzer U, Kubica K, Stieler J et al (2008) A randomized trial in patients with gemcitabine pretreated pancreatic cancer. Final results of the CONKO 003 study. In: ASCO annual meeting proceedings. J Clin Oncol 26: abstract 4508Google Scholar
- 6.Pelzer U, Schwaner I, Stieler J et al (2011) Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 47:1676–1681PubMedCrossRefGoogle Scholar
- 20.Fine R, Moorer G, Sherman W, Chu, Maurer KM, Chabot J et al (2009) Phase II trial of GTX chemotherapy in metastatic pancreatic cancer. Clin Oncol 27(15 Suppl): abstract 4623Google Scholar
- 21.Ulrich-Pur H, Raderer M, Verena Kornek G et al (2003) Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Br J Cancer 88:1180–1184Google Scholar
- 22.Jacobs AD, Burris HA, Rivkin S et al (2004) A randomized phase III study of rubitecan (ORA) vs. best choice (BC) in 409 patients with refractory pancreatic cancer report from a North-American multi-center study. J Clin Oncol 22(Suppl):Abstr 4013Google Scholar
- 23.Astsaturov IA, Meropol NJ, Alpaugh RK et al (2007) A randomized phase II and coagulation study of bevacizumab alone or with docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma. J Clin Oncol 25(18S):Abstr 4556Google Scholar
- 24.Hwang JY, Yoo C, Kim T et al (2009) A randomized phase II study of FOLFOX or FOLFIRI.3 as second-line therapy in patients with advanced pancreatic cancer previously treated with gemcitabine-based chemotherapy. J Clin Oncol 27(15S):Abstr 4618Google Scholar